Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death
about
sameAs
TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modulesTWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regenerationConcerted action of Nrf2-ARE pathway, MRN complex, HMGB1 and inflammatory cytokines - implication in modification of radiation damageSoluble Fn14 Is Detected and Elevated in Mouse and Human Kidney DiseaseFibroblast growth factor inducible 14 (Fn14) is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes. Evidence for TWEAK-independent functions of Fn14 during myogenesisThe tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expressionTNF superfamily: a growing saga of kidney injury modulators.Apoptosis-related genes change their expression with age and hearing loss in the mouse cochlea.A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure.LMX1B is essential for the maintenance of differentiated podocytes in adult kidneys.TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation.Discovery of a set of biomarkers of human lung adenocarcinoma through cell-map proteomics and bioinformatics.Immune and myodegenerative pathomechanisms in inclusion body myositisTWEAK induces liver progenitor cell proliferationTNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokineTWEAK enhances E-selectin and ICAM-1 expression, and may contribute to the development of cutaneous vasculitis.Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention.Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells.Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth.A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia.Development of an Fn14 agonistic antibody as an anti-tumor agent.TWEAK/Fn14 interaction regulates RANTES production, BMP-2-induced differentiation, and RANKL expression in mouse osteoblastic MC3T3-E1 cellsTemporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's diseaseThe cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system.HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels.Anti-TWEAK monoclonal antibodies reduce vascular damage and leucocyte infiltration in a mouse model of cutaneous reverse passive Arthus reaction.The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis.Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer.Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb.The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatmentTWEAKing deathTWEAK and the central nervous system.The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targetingAntitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumorsNuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR.Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.TWEAK as a target for therapy in systemic lupus erythematosus.The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases.TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease
P2860
Q24553352-9687C597-F6B3-463E-A10A-9DF2B953591FQ24670970-2527D064-682D-4740-80F2-CBC86623C030Q26995211-E775E8C6-1EE8-41CE-A5F5-4C6E0381DCA1Q27347256-89288343-7DD0-4D0A-838C-B93CE619B99EQ28294844-2386F7F2-BB0B-4220-96CF-BFD1FDB06968Q28299334-B041D6F6-C8BA-4160-83E6-B6D4458CEA18Q30479123-120BFD55-8A27-4CD3-8DD6-174AEBABA9E5Q30482886-AF613540-5A36-400C-855C-0AA4C4637BEDQ30496163-181A7F96-49BC-45C8-940F-AB3E71A7A263Q30555221-B38D6F0C-8931-4CA9-B333-4BDF2893427AQ31148506-7723B968-104B-4B51-A4E6-04EA6130CD8EQ33521321-1A73174F-FDF6-4344-8F62-B534CD0407FCQ33753870-17B81B0C-CA9F-4851-A196-DCEAA0F68B46Q33919951-50EFBF15-FB5B-4C94-83BD-041D3B7D4C56Q34132318-88821A9A-A840-409F-8783-915D307A89FCQ34607114-E8BC91E0-3812-4588-8CC3-F1D823F23C52Q34613065-0641495F-AB39-43CD-8E22-E0C138181982Q34785621-F2520A92-22D1-463F-AE3A-CC3FE2E213CFQ35018711-83B30B97-53BA-4A6D-9A20-DC8C8F7B6ADFQ35083662-6D9DC6AB-97EA-4DD9-B5F5-14C95C97E4E4Q35556794-977E00D6-349F-46D9-8EFC-B4DBDC2114C7Q35605699-8C35E0B7-2AE1-444E-8DE5-9CBB55269491Q35846770-1E394155-3417-46BF-922A-FB957692CF06Q35850469-E956C25A-EFA9-4401-A319-70CD3F3B8760Q35866999-F92E92B9-1E48-45EF-9A10-E51D2A19B40CQ36165761-8FFD57D4-0AD4-4576-87BC-69520344BA0BQ36217335-F8EA550D-F4F0-4618-84DD-3282172B1EF8Q36230448-DE921D11-CDDA-4606-9461-A92E597A4B42Q36469716-D5E55082-1C6A-4A6B-838D-8C9E78A38BC7Q36546646-95A71255-3D97-45D8-8B7E-8C1811CBF143Q36691896-A266FB2C-4C95-47BE-905E-3556A84F5064Q36749656-EA9448F9-B9D1-4AA4-9B1E-78140B004304Q36961175-EB748FDD-E2F5-44B5-8E62-0E136413E246Q37135363-91C826D3-FD6B-4F90-A3AF-9472A0D40BDEQ37247862-DF1FF5D6-C1FB-413D-820D-6F6BA76DFADFQ37446811-202EAB89-4CD0-4D0A-9041-E68169A2D6F7Q37453911-0B9F8B5B-BBA3-4BC4-942D-ADF10ADEB507Q37722596-F11C2AEE-B98C-4A2D-9251-B8EEA9F345D6Q38016615-FFF20CDC-C087-4C61-A675-F8D81CC83689Q38171480-28332983-3E2A-4D0F-A9F4-AFFC2517AB58
P2860
Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Fibroblast growth factor-induc ...... ys of TWEAK-induced cell death
@ast
Fibroblast growth factor-induc ...... ys of TWEAK-induced cell death
@en
Fibroblast growth factor-induc ...... ys of TWEAK-induced cell death
@nl
type
label
Fibroblast growth factor-induc ...... ys of TWEAK-induced cell death
@ast
Fibroblast growth factor-induc ...... ys of TWEAK-induced cell death
@en
Fibroblast growth factor-induc ...... ys of TWEAK-induced cell death
@nl
prefLabel
Fibroblast growth factor-induc ...... ys of TWEAK-induced cell death
@ast
Fibroblast growth factor-induc ...... ys of TWEAK-induced cell death
@en
Fibroblast growth factor-induc ...... ys of TWEAK-induced cell death
@nl
P2093
P3181
P1476
Fibroblast growth factor-induc ...... ys of TWEAK-induced cell death
@en
P2093
Hideo Yagita
Kazumi Ishidoh
Ko Okumura
Masafumi Nakayama
Norihiro Harada
Yuko Kojima
P3181
P356
10.4049/JIMMUNOL.170.1.341
P407
P577
2003-01-01T00:00:00Z